Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature

• Status: Completed
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Pneumonic adenocarcinoma (P-ADC) is defined as a primary lung ADC with a radiological pneumonic presentation, usually referred to histologically as ADC with a mixed-invasive and BAC predominant subtype in the 2004 WHO classification. Surgery is the best therapy for resectable tumors since the effectiveness of chemotherapy is disappointing. In the advanced P-ADC diffuse/multifocal types of BAC, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) (gefitinib and erlotinib) have shown promise, with some rapid, dramatic responses, possibly reflecting specific molecular differences from other non-small cell lung carcinomas.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Intergroupe Francophone de Cancerologie Thoracique
• Collaborator: AstraZeneca
• Treatments: Gefitinib

Criteria

Inclusion Criteria:

• Pathologically / cytologically proven ADC-P

• Non-resectable disease

• 3-month expected survival

• No prior radiotherapy or chemotherapy

• Age >= 18 years old

• Performance status < 4 (WHO)

• Adequate blood biological parameters

Exclusion Criteria:

• Abnormal initial fibroscopy